home.social

#alvotech — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #alvotech, aggregated by home.social.

fetched live
  1. Alvotech gets FDA VAI classification for Iceland plant | ALVO SEC Filing

    UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16…
    #Iceland #IS #Europe #Europa #EU #ALVO #Alvotech #AVT05 #AVT06 #AVT16 #biosimilars #Biotechnology #BLA #FDAInspection #iceland #island #VAIclassification
    europesays.com/3162739/

  2. Alvotech Reports Positive PK Results for AVT80

    Alvotech has announced top-line results from a pivotal pharmacokinetic study of AVT80, a proposed biosimilar to Entyvio (vedolizumab). The randomized, double-blind, 3-arm study assessed PK similarity, safety, and immunogenicity in healthy adults after a single 108 mg/0.68 mL subcutaneous injection. The data supports the development of the candidate for patients worldwide.

    #Alvotech #biosimilars #biotech #lifescience

  3. Alvotech Reports Positive PK Results for AVT80

    Alvotech has announced top-line results from a pivotal pharmacokinetic study of AVT80, a proposed biosimilar to Entyvio (vedolizumab). The randomized, double-blind, 3-arm study assessed PK similarity, safety, and immunogenicity in healthy adults after a single 108 mg/0.68 mL subcutaneous injection. The data supports the development of the candidate for patients worldwide.

    #Alvotech #biosimilars #biotech #lifescience

  4. Alvotech Reports Positive PK Results for AVT80

    Alvotech has announced top-line results from a pivotal pharmacokinetic study of AVT80, a proposed biosimilar to Entyvio (vedolizumab). The randomized, double-blind, 3-arm study assessed PK similarity, safety, and immunogenicity in healthy adults after a single 108 mg/0.68 mL subcutaneous injection. The data supports the development of the candidate for patients worldwide.

    #Alvotech #biosimilars #biotech #lifescience

  5. Alvotech Reports Positive PK Results for AVT80

    Alvotech has announced top-line results from a pivotal pharmacokinetic study of AVT80, a proposed biosimilar to Entyvio (vedolizumab). The randomized, double-blind, 3-arm study assessed PK similarity, safety, and immunogenicity in healthy adults after a single 108 mg/0.68 mL subcutaneous injection. The data supports the development of the candidate for patients worldwide.

    #Alvotech #biosimilars #biotech #lifescience

  6. Alvotech Secures Global Settlement for Aflibercept Biosimilar

    Alvotech reached a settlement to market its biosimilar globally. Entry starts Jan 1, 2026, in the UK and Canada. The EEA and other regions follow May 1, 2026. Japan allows full indications by Nov 1, 2026. Combined with a US Q4 2026 license, the company secures worldwide rights to supply partners, subject to regulatory approval.

    #biotech #biosimilars #lifescience #Alvotech

  7. Alvotech Secures Global Settlement for Aflibercept Biosimilar

    Alvotech reached a settlement to market its biosimilar globally. Entry starts Jan 1, 2026, in the UK and Canada. The EEA and other regions follow May 1, 2026. Japan allows full indications by Nov 1, 2026. Combined with a US Q4 2026 license, the company secures worldwide rights to supply partners, subject to regulatory approval.

    #biotech #biosimilars #lifescience #Alvotech

  8. Alvotech Secures Global Settlement for Aflibercept Biosimilar

    Alvotech reached a settlement to market its biosimilar globally. Entry starts Jan 1, 2026, in the UK and Canada. The EEA and other regions follow May 1, 2026. Japan allows full indications by Nov 1, 2026. Combined with a US Q4 2026 license, the company secures worldwide rights to supply partners, subject to regulatory approval.

    #biotech #biosimilars #lifescience #Alvotech

  9. Alvotech Secures Global Settlement for Aflibercept Biosimilar

    Alvotech reached a settlement to market its biosimilar globally. Entry starts Jan 1, 2026, in the UK and Canada. The EEA and other regions follow May 1, 2026. Japan allows full indications by Nov 1, 2026. Combined with a US Q4 2026 license, the company secures worldwide rights to supply partners, subject to regulatory approval.

    #biotech #biosimilars #lifescience #Alvotech

  10. Icelandic BioTech Alvotech secures €100 million term loan facility to bolster liquidity and R&D investment

    Alvotech, a Reykjavík-based BioTech company specialising in the development and manufacture of biosimilar medicines, has secured a €100…
    #Iceland #IS #Europe #Europa #EU #Alvotech #biosimilars #biotechstartup #GoldenTreeAssetManagement #iceland #island #reykjavik #RobertWessman
    europesays.com/2673155/